Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.
about
Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenograftsRelationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model systemNRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells.RNA-based ovarian cancer research from 'a gene to systems biomedicine' perspective.Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.Network-based identification of key proteins involved in apoptosis and cell cycle regulation.The prognostic of p27(kip1) in ovarian cancer: a meta-analysis.Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.
P2860
Q33750182-992A0862-BEDF-4BB0-B1DD-D73567AB20FDQ35448716-6ADC2493-C16A-4FD1-8F23-8619635AD942Q35693161-5A3A50D0-0D1A-4FC7-B61D-BF7DA310D2E0Q36387554-94D8FB4C-F774-4BD4-95D7-047600A7C1C6Q36557500-F9BBA7BB-52C4-4D3F-92DF-8AC0FA27DFE9Q37689036-56404B7C-BDB1-4301-AC9E-92D4A87B494EQ38103747-B428A51C-C3B4-4136-9429-FEE9F37A4867Q38432883-D468D2EB-BE60-4371-B243-B43317E82BD1Q38680412-AAE18865-791D-4D5B-9FB0-38DFAC22F710Q38704805-DD7388BC-C58A-487D-961C-3D7CA2476E7DQ39042958-39C13741-8E48-42C0-B0EF-F3B798FECD6DQ39181880-E7E5BABC-2766-466D-A3F5-D3A518D4BB7BQ40711411-ADB4ED08-5530-4308-9BF7-215450D4FEEBQ41915916-B9CA8D0D-997D-4E27-A3DB-89471D410C8CQ42109090-CDF1B7AD-CADF-4C6A-A784-7EAD80EB09CEQ48102534-DE90640F-A755-43B0-A763-DE992D5B2345
P2860
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Defining the molecular respons ...... ion therapy in ovarian cancer.
@ast
Defining the molecular respons ...... ion therapy in ovarian cancer.
@en
type
label
Defining the molecular respons ...... ion therapy in ovarian cancer.
@ast
Defining the molecular respons ...... ion therapy in ovarian cancer.
@en
prefLabel
Defining the molecular respons ...... ion therapy in ovarian cancer.
@ast
Defining the molecular respons ...... ion therapy in ovarian cancer.
@en
P2093
P2860
P50
P356
P1476
Defining the molecular respons ...... tion therapy in ovarian cancer
@en
P2093
D Faratian
S P Langdon
P2860
P2888
P304
P356
10.1038/BJC.2012.176
P407
P577
2012-05-01T00:00:00Z